GlassScriptPhysician profile
Alan R Levinstone
NPI 1992709265
$5,537.53
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,562 · 2020: $1,612 · 2021: $1,407 · 2022: $890 · 2023: $67.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $67.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $67.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $826.76 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $625.26 | 2019-2023 | Farxiga |
| Biogen, INC. | $340.81 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $297.06 | 2019-2023 | |
| Emd Serono, INC. | $237.95 | 2019-2021 | |
| Amgen INC. | $231.97 | 2019-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $204.48 | 2019-2021 | |
| Amarin Pharma, INC. | $199.94 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $198.64 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.53 | 2019-2021 | |
| Esperion Therapeutics, INC. | $154.10 | 2021 | |
| Astellas Pharma US INC | $151.89 | 2019-2022 | |
| Abbvie INC. | $145.37 | 2019-2022 | |
| Lilly USA, LLC | $137.02 | 2019-2021 | |
| Pfizer INC. | $132.52 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Levinstone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.